Interim report H1 2024 – 27.08.2024

H1 organic pro forma revenue growth of 7%, with pro forma adjusted EBITDA margin of 35.3%. Full year outlook raised.

• H1 organic pro forma revenue growth of 7% and 8% on an IFRS reported basis.
• Q2 organic pro forma revenue growth of 10%; Food & Health Biosolutions of 9%; and Planetary Health Biosolutions of 11%.
• H1 pro forma adjusted EBITDA margin of 35.3%, with 34.0% for Food & Health Biosolutions and 36.3% for Planetary Health Biosolutions. H1 adjusted EBITDA on IFRS reported basis of 35.5%.
• Pro forma cash flow from operating activities was strong in the first half of the year at EUR 540.7 million, including a one-off item.
• Integration progressing very well; cost synergies remain on track with 80% run rate. Sales synergies on track to contribute from 2025 onwards.
• Complete organizational structure present in all regions and functions.
• Interim dividend approved for 2024 at DKK 2.00/share (EUR 0.27). Dividend will be paid on September 3, 2024, with August 29, 2024 as the last trading day with dividend.